Literature DB >> 11642015

[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].

J D Cavallo1, F Leblanc, R Fabre, A Fourticq-Esqueöute.   

Abstract

A prospective survey was carried out in october 1999 in 15 french teaching hospitals. Average susceptibility rates, determined by minimal inhibitory concentrations, for the 738 non-repetitive strains of P. aeruginosa isolated were: ticarcillin, 58%, ticarcillin + clavulanic acid, 56%, piperacillin, 73%, piperacillin + tazobactam, 82%, ceftazidime, 76%, cefepime, 53%, cefpirome, 36%, aztreonam, 58%, imipenem, 81%, amikacin, 62%, tobramycine, 71% and, ciprofloxacin, 60%. Among the 75% serotypable strains, the most frequent serotypes were: O:6 (15.3%), O:11 (14.5%), O:1 (10.4%), O:3 (7.9%), O:4 (6.1%) and O:12 (6.1%). The serotype O:12 was the most resistant to antibiotics. Forty-two percent of the strains were resistant or presented an intermediate susceptibility to ticarcillin. Mechanisms were as follow: 14.5% non enzymatic mechanism, 12.5% overproduction of the constitutive cephalosporinase, 7.1% transferable betalactamase and, 6.9% combination of these mechanisms. Among the 67 transferable betalactamases: 48 (71.6%) were PSE-1, 12 (19.4%) TEM-2 and 6 (7.5%) oxacillinases. One extended spectrum betalactamase was characterized. Among the cephalosporines tested, cefepime was less affected by the overproduction of constitutive cephalosporinase. Ceftazidime, remained the best cephalosporin except against the strains overexpressing the chromosomal type 1 beta-lactamase. Resistance to tobramycin was mainly due to enzymatic mechanisms with a high level of resistance. Decreased susceptibility was more frequent for amikacin than for tobramycin. This was probably related with non enzymatic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642015     DOI: 10.1016/s0369-8114(01)00213-9

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  4 in total

1.  Evaluation of the automated phoenix system for potential routine use in the clinical microbiology laboratory.

Authors:  J-L Donay; D Mathieu; P Fernandes; C Prégermain; P Bruel; A Wargnier; I Casin; F X Weill; P H Lagrange; J L Herrmann
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

2.  New Sequence Type ST3449 in Multidrug-Resistant Pseudomonas aeruginosa Isolates from a Cystic Fibrosis Patient.

Authors:  Catalina Díaz-Ríos; Marta Hernández; David Abad; Laura Álvarez-Montes; Athanasia Varsaki; David Iturbe; Jorge Calvo; Alain A Ocampo-Sosa
Journal:  Antibiotics (Basel)       Date:  2021-04-23

3.  Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.

Authors:  David M Livermore; Shazad Mushtaq; Daniele Meunier; Katie L Hopkins; Robert Hill; Rachael Adkin; Aiysha Chaudhry; Rachel Pike; Peter Staves; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

4.  Molecular Characterization of Antibiotic Resistance Associated with TEM and CTX-M ESBL in Uropathogenic E. coli Strains Isolated from Outpatients.

Authors:  Sorour Farzi; Reza Ranjbar; Mohammad Niakan; Mohammad Hossein Ahmadi
Journal:  Iran J Pathol       Date:  2021-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.